DocGo (DCGO) Stock Forecast & Price Target

DocGo is viewed positively because the Hicuity Health acquisition meaningfully strengthens its “closed-loop care anywhere” strategy by pairing hospital-facing virtual care with its in-home and mobile health capabilities, expanding cross-sell potential across more than 260 hospital relationships, 4,700 monitoring beds, and about 160k patients per year. Hicuity adds $65 million of TTM revenue and $4.5 million of adjusted EBITDA, while management sees roughly $4.3 million of annual run-rate savings from staffing, organizational, and facilities optimization, supporting a clearer path to profitability. Despite the added $52 million of debt, the company also has an additional $50 million financing backstop and expects core operations to improve, with payer volumes rising to 1.7 million lives and SteadyMD, transportation, and mobile health providing diversified growth.

DocGo is viewed negatively because 2Q26 showed weakening fundamentals, with revenue of $73.4mm below expectations, adjusted EBITDA of ($4.2mm), gross margin compressing to 30.5%, and operating expenses rising to $40.3mm. Its mobile health segment remains the main concern, as revenue fell 30.4% year over year to $21.4mm and margin pressure worsened after the migrant contract winddown, while the company is still trying to prove that cost cuts can restore profitability by 2026. Balance-sheet risk is also elevated because the acquisition is largely debt-funded, cash was only about $32.2mm, and if fully drawn Perceptive debt could reach ~$102mm at a floating SOFR + 7.5% rate, leaving execution on synergies, receivables, and deleveraging highly timing sensitive.